Financial Data and Key Metrics Changes - Q1 2025 revenues were $5 million, down $300,000 year on year, but the LIFO business was up year on year [5][12] - On a non-GAAP basis, adjusted operating loss was $4.6 million compared to $5.5 million for the same periods [19] - GAAP gross margin was 42.2% compared to 26.4% in Q1 2024, while non-GAAP adjusted gross margin was 42.2% compared to 33.7% [17][18] Business Line Data and Key Metrics Changes - Revenue from ReWalk robotics products was $1.6 million, while Alter G products generated $3.4 million, with Alter G sales growing by 19% year on year [14] - The number of ReWalk rentals increased to 36, primarily in Germany, indicating strong future sales potential [6][15] - Alter G has shown significant growth of 1970% in the last two quarters [7] Market Data and Key Metrics Changes - The U.S. pipeline has over 120 qualified leads, up over 70% from two quarters ago [6][15] - The company has expanded partnerships with Alter G distributors, including four new business partners [6] Company Strategy and Development Direction - The company is focused on profitable revenue growth, tight expense control, and cash management [5] - A partnership with CoreLife aims to enhance progress in the workers' compensation segment [6] - The company anticipates a sales range of $28 million to $30 million for 2025, with expectations of a reduced operating loss by Q4 [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth based on a strong pipeline and recent FDA approvals [6][20] - The leadership transition is expected to be smooth, with a solid foundation in place for future growth [11] Other Important Information - The company ended Q1 with $5.7 million in cash and equivalents and no debt, raising an additional $500,000 post-quarter [19] - The company is working collaboratively with Medicare Administrative Contractors to improve claims processing predictability [10] Q&A Session Questions and Answers Question: What is the assessment of recent tariff situations? - The company is monitoring the situation closely and has planned for alternatives within the market, with minimal impact expected on the ReWalk production in Israel [25][26] Question: How does the company support its full-year revenue guidance despite lower Q1 revenue? - Confidence is based on strong momentum in the Ultra G product line and a robust pipeline of leads, indicating growth potential [28] Question: Can you elaborate on the ReWalk seven's differences from the previous version? - The ReWalk seven features significant improvements in usability, power, and control, while maintaining a similar price point [36][39] Question: How does the expanded Mylan partnership benefit the commercial sales force? - The partnership allows access to a new segment for home use, leveraging historical data to drive sales [42] Question: What is the market size for workers' compensation in the U.S.? - The workers' compensation market represents about 6% to 7% of the overall market, providing a significant opportunity for growth [47] Question: How has the Alter G acquisition performed? - The integration has stabilized, and recent product launches have shown strong growth, particularly in international markets [54][56]